3113309-33-1
Chemical Structure
KVL-9
- CAS. Nr.: 3113309-33-1
- Formula:C140H192F2N38O34S2
- Molecular Weight:3053.38
InChIKey: YHTHIIPALREYFN-HVPXCAEASA-N
SMILES: C[C@@]1(C2=NC(C3=NC(N4[C@H](CN(CCC4)CCCCOC5=CN(N=N5)[C@@H](C(C)C)C(N6[C@@H](C[C@H](C6)O)C(N[C@H](C7=C(C=C(C8=C(C)N=CS8)C(F)=C7)OCC9=CC=C(C=C9)NC([C@H](C)NC([C@H](C)NC(CCC%10=C(C(F)=C(N%11C(C=CC%11=O)=O)C=C%10)OCCCC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)C)=NC=C3)=NO2)C%12=C(CCC1)SC(N)=C%12C#N
Biological Activity: KVL‑9 is an intermediate for constructing KRAS-degrading antibody-drug conjugates (DAC), consisting of a KRAS small-molecule binder, a spacer, a VHL-recruiting ligand, and a cleavable antibody linker. By conjugating with tumor antigen-targeting antibodies, KVL‑9 enables antigen-dependent intracellular delivery and induces VHL‑mediated ubiquitin‑proteasome degradation of KRAS protein. KVL‑9 can be used for the synthesis of DACs. KVL‑9 is applicable to cancer research[1].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
KVL-9 | KVL‑9 is an intermediate for constructing KRAS-degrading antibody-drug conjugates (DAC), consisting of a KRAS small-molecule binder, a spacer, a VHL-recruiting ligand, and a cleavable antibody linker. By conjugating with tumor antigen-targeting antibodies, KVL‑9 enables antigen-dependent intracellular delivery and induces VHL‑mediated ubiquitin‑proteasome degradation of KRAS protein. KVL‑9 can be used for the synthesis of DACs. KVL‑9 is applicable to cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
